Cargando…

A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke

The purpose of this study was to perform a pooled analysis of randomized controlled trials (RCT) of intravenous thrombolysis (IVT) versus bridging therapy of intravenous thrombolysis and mechanical thrombectomy (IVMT), comparing the efficacy and safety of the two in patients with acute ischemic stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Raoqiong, Li, Shuangyang, Hao, Linyao, Wang, Zhichuan, Ge, Zhengxin, Yang, Sijin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524994/
https://www.ncbi.nlm.nih.gov/pubmed/36181087
http://dx.doi.org/10.1097/MD.0000000000030879
_version_ 1784800611965861888
author Wang, Raoqiong
Li, Shuangyang
Hao, Linyao
Wang, Zhichuan
Ge, Zhengxin
Yang, Sijin
author_facet Wang, Raoqiong
Li, Shuangyang
Hao, Linyao
Wang, Zhichuan
Ge, Zhengxin
Yang, Sijin
author_sort Wang, Raoqiong
collection PubMed
description The purpose of this study was to perform a pooled analysis of randomized controlled trials (RCT) of intravenous thrombolysis (IVT) versus bridging therapy of intravenous thrombolysis and mechanical thrombectomy (IVMT), comparing the efficacy and safety of the two in patients with acute ischemic stroke (AIS). METHODS: All eligible RCT articles from database establishment to December 8, 2021 were searched in databases such as PubMed, Ovid, Embase, Web of science, Cochrane Library, etc. Efficacy outcomes were assessed by modified RANKIN scal (mRS) score, complete recanalization or reperfusion (TICI), National Institute of Health Stroke Scal (NIHSS) score, 90-day mortality, 24 to 36 h incidence of symptomatic intracranial hemorrhage (sICH). RESULTS: Our study included 6 RCT involving 1717 patients. The proportion of the primary efficacy outcome (mRS score 0‐2 at 90 days) was significantly different between IVT and IVMT (OR 0.51; 95% CI 0.35‐0.76). For the secondary efficacy outcome, the study found a significant difference in the proportion of TICI (pooled OR was 0.055, 95% CI 0.07‐0.33). There was a significant difference in the 24 h NIHSS score between the IVT group and the IVMT group (pooled MD was 3.25, 95% CI 0.80‐5.70). There were no significant differences in the NIHSS score at 90 days, the death rate at 90 days, and the sICH at 24 to 36 hours between the two groups. CONCLUSIONS: This study confirms that IVMT is more effective and safe than IVT alone in patients with AIS. However, more and higher-quality randomized clinical trials comparing IVMT to IV alone are warranted for validation.
format Online
Article
Text
id pubmed-9524994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95249942022-10-03 A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke Wang, Raoqiong Li, Shuangyang Hao, Linyao Wang, Zhichuan Ge, Zhengxin Yang, Sijin Medicine (Baltimore) Research Article The purpose of this study was to perform a pooled analysis of randomized controlled trials (RCT) of intravenous thrombolysis (IVT) versus bridging therapy of intravenous thrombolysis and mechanical thrombectomy (IVMT), comparing the efficacy and safety of the two in patients with acute ischemic stroke (AIS). METHODS: All eligible RCT articles from database establishment to December 8, 2021 were searched in databases such as PubMed, Ovid, Embase, Web of science, Cochrane Library, etc. Efficacy outcomes were assessed by modified RANKIN scal (mRS) score, complete recanalization or reperfusion (TICI), National Institute of Health Stroke Scal (NIHSS) score, 90-day mortality, 24 to 36 h incidence of symptomatic intracranial hemorrhage (sICH). RESULTS: Our study included 6 RCT involving 1717 patients. The proportion of the primary efficacy outcome (mRS score 0‐2 at 90 days) was significantly different between IVT and IVMT (OR 0.51; 95% CI 0.35‐0.76). For the secondary efficacy outcome, the study found a significant difference in the proportion of TICI (pooled OR was 0.055, 95% CI 0.07‐0.33). There was a significant difference in the 24 h NIHSS score between the IVT group and the IVMT group (pooled MD was 3.25, 95% CI 0.80‐5.70). There were no significant differences in the NIHSS score at 90 days, the death rate at 90 days, and the sICH at 24 to 36 hours between the two groups. CONCLUSIONS: This study confirms that IVMT is more effective and safe than IVT alone in patients with AIS. However, more and higher-quality randomized clinical trials comparing IVMT to IV alone are warranted for validation. Lippincott Williams & Wilkins 2022-09-30 /pmc/articles/PMC9524994/ /pubmed/36181087 http://dx.doi.org/10.1097/MD.0000000000030879 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Raoqiong
Li, Shuangyang
Hao, Linyao
Wang, Zhichuan
Ge, Zhengxin
Yang, Sijin
A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke
title A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke
title_full A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke
title_fullStr A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke
title_full_unstemmed A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke
title_short A meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke
title_sort meta-analysis of intravenous thrombolysis versus bridging therapy for ischemic stroke
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524994/
https://www.ncbi.nlm.nih.gov/pubmed/36181087
http://dx.doi.org/10.1097/MD.0000000000030879
work_keys_str_mv AT wangraoqiong ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT lishuangyang ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT haolinyao ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT wangzhichuan ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT gezhengxin ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT yangsijin ametaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT wangraoqiong metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT lishuangyang metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT haolinyao metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT wangzhichuan metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT gezhengxin metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke
AT yangsijin metaanalysisofintravenousthrombolysisversusbridgingtherapyforischemicstroke